The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link?
- PMID: 16907905
- PMCID: PMC1809707
- DOI: 10.1111/j.1365-2249.2006.03162.x
The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link?
Abstract
The world is confronted with major tuberculosis (TB) outbreaks at a time when the protection of bacillus Calmette-Guérin (BCG) vaccine has become inconsistent and controversial. Major TB outbreaks are caused by a group of genetically similar strains of Mycobacterium tuberculosis (Mtb) strains, including the Beijing family genotypes. The Beijing family genotypes exhibit important pathogenic features such high virulence, multi-drug resistance and exogenous reinfection. These family strains have developed mechanisms that modulate/suppress immune responses by the host, such as inhibition of apoptosis of infected macrophages, diminished production of interleukin (IL)-2, interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha and elevated levels of IL-10 and IL-18. They demonstrate distinct expression of proteins, such as several species of alpha-crystallin (a known Mtb virulence factor), but decreased expression of some antigens such as heat shock protein of 65 kDa, phosphate transport subunit S and a 47-kDa protein. In addition, the Beijing family strains specifically produce a highly bioactive lipid (a polyketide synthase)-derived phenolic glycolipid. This altered expression of proteins/glycolipids may be important factors underlying the success of the Beijing family strains. The Beijing family strains are speculated to have originated from South-east Asia, where BCG vaccination has been used for more than 60 years. The hypothesis that mass BCG vaccination may have been a selective factor that favoured genotypic and phenotypic characteristic acquired by the Beijing family strains is discussed.
References
-
- World Health Organization (WHO) Geneva: World Health Organization; 1996. Global programme for vaccines and immunization – Expanded Programme on Immunization. Immunization Policy. WHO/EPI/Geneva/95.03, Rev. 1.
-
- Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346:1339–45. - PubMed
-
- International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programmes using bacilli Calmette–Guérin (BCG) in countries with low prevalence of tuberculosis. Tuberc Lung Dis. 1994;75:179–80. - PubMed
-
- Comstock GW. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials. 1994;15:247–76. - PubMed
-
- Fine PE. The BCG story: lessons from the past and implications for the future. Rev Infect Dis. 1989a;11:s353–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
